Overview

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Epratuzumab